Covid-19: why Pfizer’s Paxlovid pill won’t benefit everyone at risk

DECRYPTION – Pfizer’s drug, supposed to help unclog hospitals, has contraindications for some people.

Paxlovid, Pfizer’s new anti-covid pill, will it be the miracle cure for ending the crisis? The very first oral treatment in France, the drug received the green light on Friday from the High Authority for Health. Reserved for the immunocompromised, it will be available in the next few days in pharmacies, ready to be prescribed by general practitioners. “It will be a game-changer for our health systems, by unclogging hospitals“, rejoiced in our pages the boss of Pfizer, Albert Bourla. “This is very good news, especially for patients with Covid-19.“Added the CEO of Novasep, whose pharmaceutical group has been entrusted with the manufacture of the drug in France.

The administration is simple: three tablets twice a day for five days, as soon as symptoms appear. In Israel, where the pill has been used since early January, a study by the health fund Maccabi reveals that 60% of patients using Paxlovid begin to feel…

This article is for subscribers only. You have 86% left to discover.

Pushing back the limits of science is also freedom.

Keep reading your article for 1€ the first month

Already subscribed? Login


Leave a Reply

Your email address will not be published. Required fields are marked *